The hidden switch behind one of the biggest paradoxes in aging muscle
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Our muscles are built from bundles of fibers. Some are fast-twitch, tuned for quick, powerful bursts of effort but quick to tire. Others are slow-twitch, built for endurance and packed with more mitochondria, the structures commonly called the "powerhouses of the cell."
As we age, our muscles grow weaker, and the mitochondria inside them work less well. Yet at the same time, our muscles shift toward slow-twitch fibers that depend most on mitochondria. A similar shift occurs in many diseases that cause muscle wasting. It's paradoxical: Why would aging muscle lean harder on the very machinery that is failing?
Scientists at the University of Copenhagen pinpoint a molecular cause of muscle aging, and a possible fix: a druggable nuclear receptor, ERRγ, that could be targeted to preserve muscle function. The findings are published in Nature Aging.
Cardiolipin links aging to muscle changes
To understand the enigma, the researchers turned to cardiolipin, a fat molecule found essentially nowhere else in the cell but the inner membrane of mitochondria, where it is essential for the membrane's unique folded structure. Without it, mitochondria are unable to produce enough energy or the metabolic signals and building blocks that cells need.
The scientists found that cardiolipin levels decline in mouse and human muscle mitochondria with age and disease, leaving the mitochondria distorted and unable to operate properly.
To test whether falling cardiolipin was a cause rather than a consequence, the scientists lowered cardiolipin levels in young mice to mimic the drop seen in aging. They saw the same shift from fast-twitch to slow-twitch muscle fibers that occurs naturally in aged mice and humans. When cardiolipin levels were partially restored to roughly two-thirds of normal, the muscle wasting began to reverse, and the animals' early deaths were prevented entirely.
Damaged mitochondria sound an alarm
So why do muscles respond this way? The answer was surprising: It's a defense mechanism.
As cardiolipin levels decline, strained mitochondria generate far more reactive oxygen species (ROS), which damage cells. But ROS also serves as a signal: When the researchers used an antioxidant to mop up ROS in cardiolipin-depleted muscle cells, the shift toward slow-twitch fibers was blunted.
Trading muscle power for protection
The switch itself runs through a protein called ERRγ, which triggers the cells to remodel their mitochondria and change fiber type from fast-twitch to slow-twitch. When the scientists blocked ERRγ in cultured muscle cells, the fiber switch was completely shut down.
The remodeled slow-twitch fibers better protect the cell from ROS because of what they do with sugar. Cardiolipin-deficient mice pulled much more glucose out of the bloodstream, but not to burn for energy. By tracing labeled sugar through the muscle, the researchers showed it was instead used to manufacture the cell's own antioxidants.
"The fiber switch is not the muscle failing, but the muscle trading power for protection. That's also why interfering with it can backfire: When we gave the mice antioxidants to mop up the ROS, their muscles fared worse, not better," says Fabian Finger, an assistant professor at the University of Copenhagen and the study's first and co-corresponding author.
Drug targets and human questions
The work was carried out in mice, and the human samples served only to confirm that cardiolipin also declines with age in people. However, cardiolipin can already be targeted: The FDA recently granted accelerated approval to elamipretide, a drug proposed to stabilize cardiolipin, for the rare genetic disorder Barth syndrome.
ERRγ is also a promising target. It belongs to a class of molecules called nuclear receptors, which are targeted by roughly 10% to 15% of all FDA-approved small-molecule medications, and activators of ERRγ are already in preclinical development for other indications.
"What encourages me most is that even a partial recovery of cardiolipin was enough to bring the muscle back. The question now is whether we can increase cardiolipin in aging muscle or target ERRγ to promote healthy adaptations. This is where the therapeutic potential lies," says senior author Zachary Gerhart-Hines, an associate professor at the NNF Center for Basic Metabolic Research at the University of Copenhagen.
Publication details
Mitochondrial membrane lipid cardiolipin controls fiber-type adaptations in aging muscle via estrogen-related receptor γ, Nature Aging (2026). DOI: 10.1038/s43587-026-01227-7
Journal information: Nature Aging
Key medical concepts
CardiolipinsReactive Oxygen SpeciesMitochondria
Clinical categories
Healthy aging Provided by University of Copenhagen Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: The hidden switch behind one of the biggest paradoxes in aging muscle (2026, September 29) retrieved 29 September 2026 from https://medicalxpress.com/news/2026-09-hidden-biggest-paradoxes-aging-muscle.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.